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A B S T R A C T
Purpose
Dabrafenib plus trametinib improved relapse-free survival (RFS) versus placebo (hazard ratio [HR],
0.47; P , .001) in patients with resected BRAF V600–mutant stage III melanoma (BRF115532;
COMBI-AD; ClinicalTrials.gov identiﬁer: NCT01682083). We present an updated RFS analysis on the
basis of extended study follow-up and a cure-rate model analysis to estimate the fraction of patients
expected to remain relapse free long term.
Methods
In this phase III trial, patients with resected BRAF V600–mutant stage III melanoma were randomly
assigned to 12 months of adjuvant dabrafenib plus trametinib versus placebo. We report updated
RFS (primary end point) and distant metastasis–free survival. RFS was also analyzed by subgroups
deﬁned by baseline disease stage (American Joint Committee on Cancer 7th and 8th editions), nodal
metastatic burden, and ulceration status. The fraction of patients who remained relapse free long
term was estimated using a Weibull mixture cure-rate model.
Results
At median follow-up of 44 months (dabrafenib plus trametinib) and 42 months (placebo), 3- and
4-year RFS rateswere 59% (95%CI, 55% to 64%) and 54% (95%CI, 49% to 59%) in the dabrafenib
plus trametinib arm and 40% (95% CI, 35% to 45%) and 38% (95% CI, 34% to 44%) in the placebo
arm, respectively (HR, 0.49; 95% CI, 0.40 to 0.59). Distant metastasis–free survival also favored
dabrafenib plus trametinib (HR, 0.53; 95% CI, 0.42 to 0.67). The estimated cure rate was 54% (95%
CI, 49% to 59%) in the dabrafenib plus trametinib arm comparedwith 37% (95%CI, 32% to 42%) in
the placebo arm. Subgroup analysis of RFS demonstrated similar treatment beneﬁt regardless of
baseline factors, including disease stage, nodal metastatic burden, and ulceration.
Conclusion
Longer follow-up conﬁrmed RFS beneﬁt with dabrafenib plus trametinib. Subgroup analysis sug-
gested that dabrafenib plus trametinib beneﬁted patients regardless of baseline factors.
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INTRODUCTION
The development of targeted therapies and im-
mune checkpoint inhibitors has led to substantial
improvements in outcomes for patients with
unresectable or metastatic melanoma.1 Recently,
advances in systemic therapy in the metastatic
setting have translated to effective adjuvant
therapy for patients with resected, regionally
advanced disease who have a high risk of relapse.2-6
The anti–cytotoxic T-cell lymphocyte-antigen 4
antibody ipilimumab, anti–programmed death-1
antibodies nivolumab and pembrolizumab, and
the combination of dabrafenib and trametinib
have demonstrated signiﬁcant relapse-free survival
(RFS) beneﬁt as adjuvant therapies in patients with
resected melanoma.2-6
The COMBI-AD trial was the ﬁrst pro-
spective phase III trial evaluating BRAF inhibitor
and MEK inhibitor combination therapy as
adjuvant treatment in patients with completely
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resected BRAF V600 mutation–positive stage III melanoma6;
12 months of adjuvant dabrafenib plus trametinib signiﬁ-
cantly improved RFS compared with placebo. At the primary
analysis—median follow-up of 34 months (dabrafenib plus
trametinib) and 33 months (placebo)—estimated 3-year RFS
was 58% in the combination therapy arm versus 39% in the
placebo arm (hazard ratio [HR], 0.47; P , .001). An interim
analysis of overall survival (OS) demonstrated an improvement in
the combination therapy arm, with a 3-year OS of 86% versus 77%
in the placebo group (HR, 0.57; 95% CI, 0.42 to 0.79; P = .0006),
but this improvement did not cross the prespeciﬁed interim
analysis signiﬁcance threshold of P = .000019. Adjuvant
dabrafenib plus trametinib also reduced the risk of distant
metastatic relapse or death (HR, 0.51; P , .001) and was associated
with no new toxicities compared with those observed in the
metastatic melanoma setting.7,8 On the basis of these results,
the combination of dabrafenib plus trametinib has been approved
by the US Food and Drug Administration and the European
Commission as adjuvant therapy for patients with completely
resected BRAF V600E/K–mutant stage III melanoma.
Here, we present updated RFS and distant metastasis–free
survival (DMFS) analyses resulting from an extended follow-up of
patients in the COMBI-AD trial. An updated OS analysis was not
performed because the prespeciﬁed number of events has not been
reached. The data from this analysis were then also used to generate
a statistical Weibull mixture cure-rate model to provide an estimate
of the fraction of patients who will remain relapse free long term.
To our knowledge, this is the ﬁrst use of this methodology in
a trial that evaluated adjuvant therapy in patients with resected
melanoma. Finally, we present results of RFS analyses from
clinically relevant subgroups, including by baseline disease stage
(per American Joint Committee on Cancer [AJCC] 7th9 and
8th10 editions), baseline nodal metastatic burden (micro- or
macrometastasis), and ulceration status, to evaluate whether any
baseline factors may be predictive of response to adjuvant dab-
rafenib plus trametinib therapy.
METHODS
Study Design and Participants
COMBI-AD was a randomized, double-blind, placebo-controlled,
phase III trial comparing dabrafenib 150 mg twice per day plus trametinib
2 mg once per day versus two matched placebos (Fig 1). This trial enrolled
patients from 169 sites across 25 countries from January 2013 to December
2014. Full eligibility criteria have been reported previously.6 Eligible pa-
tients (age $ 18 years) underwent complete resection of histologically
conﬁrmed stage IIIA (lymph node metastasis . 1 mm), IIIB, or IIIC
cutaneous melanoma (per AJCC 7th edition) that was positive for a BRAF
V600E or V600K mutation conﬁrmed in primary tumor or lymph node
tissue by a central reference laboratory. Patients were required to have
undergone and recovered from a complete lymphadenectomy without
clinical or radiographic indication of regional nodal disease within
12 weeks of random assignment and to have an Eastern Cooperative
Oncology Group performance status of 0 or 1.
Patients were stratiﬁed by BRAF mutation status (V600E or V600K)
and disease stage (IIIA, IIIB, or IIIC according to AJCC 7th edition).
Treatment continued for 12 months unless preceded by disease relapse,
unacceptable toxicity, withdrawal of consent, or death, whichever occurred
ﬁrst. Patients were observed for disease relapse until ﬁrst relapse was
observed and were then observed for survival. Disease assessments via
imaging using computed tomography, magnetic resonance imaging, or
both were performed every 3 months for the initial 24 months, then every
6 months until study completion or disease relapse. Dermatologic eval-
uations were performed every 2 months during treatment, every 3 months
during follow-up for the ﬁrst 24 months, and every 6 months thereafter.
Dose modiﬁcations or interruptions were allowed.6 To date, two RFS
analyses have been conducted: the primary analysis previously reported
and the extended follow-up reported here. The trial is ongoing. An interim
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Fig 1. CONSORT diagram.
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analysis of OS was reported with the primary RFS analysis.6 The next OS
analysis will be conducted when 50% of events have occurred.
End Points
The primary end point was RFS, deﬁned as the time from random
assignment until disease relapse (or new primary melanoma) or death
from any cause. DMFSwas deﬁned as the time from random assignment to
the date of ﬁrst distant metastasis or date of death. Other secondary end
points, including OS, freedom from relapse, and safety, were deﬁned pre-
viously.6 Assessment of RFS in subgroups on the basis of baseline disease stage
(per AJCC 7th edition) and nodal tumor burden were prespeciﬁed ex-
ploratory analyses. Evaluation of RFS on the basis of AJCC 8th edition disease
stage at baseline and tumor ulceration status were post hoc analyses. All
disease-relapse analyses were based on investigator assessment in the intent-
to-treat population (all randomly assigned patients).
Statistical Analysis
We used the Kaplan-Meier method to estimate RFS and DMFS. A
stratiﬁed log-rank test to compare differences between treatment groups
was used for the primary analysis. HRs and 95% CIs were calculated using
the Pike estimator.11,12 A mixed Weibull cure-rate model was used to
estimate long-term relapse–free fractions of patients in each treatment
arm. Cure-rate models represent a statistical modeling approach that was
developed to model time-to-event data in situations in which it is rea-
sonable to assume that a subset of patients will remain event free long term
and are therefore cured.13,14
Trial Oversight
The trial was originally sponsored by GlaxoSmithKline; dabrafenib
and trametinib were designated as assets of Novartis on March 2, 2015,
after which Novartis took over sponsorship of the trial. The trial was
conducted in accordance with the provisions of the Declaration of Helsinki
and Good Clinical Practice guidelines. The protocol was approved by the
institutional review board or independent ethics committee at each trial
center. All patients provided written informed consent for data collection
supporting these analyses. All authors developed the initial draft of the
manuscript and made the decision to submit it for publication. All authors
contributed to subsequent drafts. The authors afﬁrm the accuracy and
completeness of the data and adherence of the trial to the protocol.
RESULTS
A total of 870 patients (dabrafenib plus trametinib, n = 438;
placebo, n = 432) were randomly assigned to receive 12 months of
adjuvant treatment. Baseline characteristics were well balanced be-
tween treatment arms (Appendix Table A1, online only). At the time of
this analysis (April 30, 2018), no patients remained on treatment—last
dose of study drug was administered to the last patient in December
2015. Median patient follow-up was 44 months in the dabrafenib plus
trametinib arm and 42 months in the placebo arm (minimum study
follow-up, 40 months; Appendix Table A2, online only).
During the additional follow-up from the primary analysis,6
RFS events were reported in 11 patients—two patients with new
primary melanoma—in the dabrafenib plus trametinib arm and in
six patients in the placebo arm. Overall, 174 patients (40%) in the
dabrafenib plus trametinib arm and 253 (59%) in the placebo arm
experienced relapse, and the majority in both arms experienced
distant relapse (Table 1). The most common sites of distant relapse
were lung (8%), liver (5%), and CNS (5%) in the dabrafenib plus
trametinib arm and lung (14%), lymph node (7%), and liver (5%)
in the placebo arm.
Updated RFS and DMFS
Investigator-assessed median RFS was not reached (95% CI,
46.9 months to not reached) in the dabrafenib plus trametinib arm
compared with 16.6 months (95% CI, 12.7 months to
22.1 months) in the placebo arm (HR, 0.49; 95% CI, 0.40 to 0.59;
Fig 2A). Three- and 4-year RFS rates were 59% (95% CI, 55% to
64%) and 54% (95% CI, 49% to 59%) in the dabrafenib plus
trametinib group and 40% (95% CI, 35% to 45%) and 38% (95%
CI, 34% to 44%) in the placebo group, respectively. Few RFS events
occurred after 3 years of follow-up in both treatment arms (Ap-
pendix Table A3, online only).
Updated analysis of DMFS yielded an HR of 0.53 (95% CI,
0.42 to 0.67), which indicated a 47% reduction in the risk of
developing distant metastases or death when patients were treated
with dabrafenib plus trametinib (Fig 2B).
Cure-Rate Model
On the basis of aWeibull mixture cure-rate model for RFS, the
estimated fraction of patients who may never experience relapse
was 54% (95% CI, 49% to 59%) in the dabrafenib plus trametinib
arm versus 37% (95% CI, 32% to 42%) in the placebo arm (Fig 3).
Subgroup Analysis of RFS
RFS on the basis of disease stage (AJCC 7th and 8th
editions). Disease stage on the basis of AJCC 7th edition—stage
IIIA, IIIB, and IIIC—was a stratiﬁcation factor in the trial (Ap-
pendix Table A4, online only). Subgroup analysis on the basis of
disease stage per AJCC 7th edition demonstrated that dabrafenib
plus trametinib improved RFS across all disease stage subgroups
compared with placebo (stage IIIA: HR, 0.58; 95% CI, 0.32 to 1.06;
stage IIIB: HR, 0.49; 95% CI, 0.37 to 0.66; stage IIIC: HR, 0.46;
95% CI, 0.34 to 0.61; Fig 4). Of note, when patients with stage IIIB
or IIIC—those at highest risk for disease relapse—were combined,
a 52% reduction in the risk of relapse or death was observed that
favored the dabrafenib plus trametinib arm (HR, 0.48; 95% CI,
0.39 to 0.59; Fig 4). Because COMBI-AD was initiated before the
release of the recent AJCC 8th edition, stage grouping was based
Table 1. Relapse-Free Survival Event Details
Variable
Dabrafenib Plus
Trametinib (n = 438)
Placebo
(n = 432)
Experienced relapse 174 (40) 253 (59)
Local/regional relapse only 56 (13) 110 (25)
Distant relapse only 102 (23) 130 (30)
Concurrent local and distant relapse 9 (2) 6 (1)
Secondary primary melanoma* 9 (2) 8 (2)
Died (event)† 3 (, 1) 1 (, 1)
NOTE. Data are given as No. (%). No. of events at the time of data cutoff for the
updated relapse-free survival analysis.
*Two patients in the dabrafenib plus trametinib arm and one patient in the
placebo arm had both disease relapse and secondary primary melanoma ob-
served on the same day.
†Includes only patients who died before any observation of relapse or new
primary melanoma event.
jco.org © 2018 by American Society of Clinical Oncology 3443
RFS Beneﬁt With Adjuvant Dabrafenib Plus Trametinib
Downloaded from ascopubs.org by University of Queensland on February 27, 2019 from 130.102.042.098
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
on AJCC 7th edition. Post hoc analysis of RFS was conducted on the
basis of baseline disease stage according to AJCC 8th edition, which,
unlike AJCC 7th edition, includes Tstage in addition toN stage (stage
IIIA, IIIB, and IIIC, as well as the new stage IIID category; Appendix
Table A4). Similar to the analysis by AJCC 7th edition criteria,
dabrafenib plus trametinib improved RFS across all AJCC 8th edition
stage subgroups compared with placebo (stage IIIA: HR, 0.63; 95%
CI, 0.26 to 1.56; stage IIIB: HR, 0.48; 95%CI, 0.34 to 0.67; stage IIIC:
HR, 0.50; 95%CI, 0.38 to 0.64; stage IIID: HR, 0.34; 95% CI, 0.14 to
0.79; Fig 5).
RFS on the basis of nodal metastatic burden and ulceration. Additional
analyses demonstrated that RFS favored dabrafenib plus trametinib
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Fig 4. Kaplan-Meier curve of relapse-free sur-
vival by disease stage per American Joint Com-
mittee on Cancer (AJCC) 7th edition. Data from
patients with baseline stage (A) IIIA, (B) IIIB, (C)
IIIC, and (D) IIIB/C disease per AJCC 7th edition are
shown with a data cutoff of April 30, 2018.
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Fig 5. Post hoc analysis of relapse-free sur-
vival by disease stage on the basis of American
Joint Committee on Cancer (AJCC) 8th edition.
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(B) IIIB, (C) IIIC, and (D) IIID disease per AJCC
8th edition are shown with a data cutoff of April
30, 2018.
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across all prespeciﬁed subgroups (Fig 6). Treatment with dab-
rafenib plus trametinib led to a similar reduction in the risk of
relapse or death in patients with baseline micrometastases (HR,
0.49; 95% CI, 0.34 to 0.70) and in those with baseline macro-
metastases (HR, 0.43; 95% CI, 0.31 to 0.58) compared with
treatment with placebo. Post hoc analysis of RFS by baseline
tumor ulceration status—ulcerated versus nonulcerated—also
showed similar beneﬁt that favored dabrafenib plus trametinib
compared with placebo regardless of status. In patients without
baseline tumor ulceration, HR for RFS was 0.53 (95% CI, 0.41 to
0.69). Among patients with tumor ulceration at baseline, HR was
0.45 (95% CI, 0.34 to 0.60). Across all baseline factors, consistent
beneﬁt favoring dabrafenib plus trametinib versus placebo was
observed.
DISCUSSION
In this updated analysis, we conﬁrmed the clinically relevant RFS
beneﬁt favoring dabrafenib plus trametinib versus placebo. RFS
Kaplan-Meier curves continued to be separated after the 12-month
treatment phase. With extended follow-up, RFS Kaplan-Meier
curves are fully mature up to approximately 40 months and
thus provide stable 3-year RFS rates that demonstrate a nearly 20%
absolute difference between arms. Moreover, the number of RFS
events in both arms decreased over time, with few events observed
after 3 years of follow-up, which is consistent with what has been
reported in other studies.15
RFS Kaplan-Meier curves generated in this updated analysis
suggest the potential formation of an RFS plateau; however, ad-
ditional follow-up is needed to conﬁrm this. Of note, a similar
observation was made in the EORTC 18071 trial that evaluated
adjuvant ipilimumab versus placebo in patients with resected stage
III melanoma.2,16 In that trial, improved RFS in patients who were
treated with ipilimumab compared with placebo observed at the
primary analysis (median follow-up, 2.7 years; HR, 0.75) was also
observed with extended follow-up to 5.3 years, with a lower rate of
RFS events reported over time. Anti–programmed death-1 ther-
apies nivolumab and pembrolizumab have also demonstrated
signiﬁcant RFS beneﬁt compared with ipilimumab in patients with
resected stage IIIB/C or IV disease3,4 and compared with placebo in
patients with resected stage IIIA/B/C disease,5 respectively. Thus
far, follow-up in these trials has been limited to 24 months for the
CheckMate-238 trial and a 15-month median follow-up in the
KEYNOTE-054 trial.4,5 Additional follow-up is necessary to un-
derstand whether the number of RFS events diminishes over time
with these therapies as well.
Among patients with relapsed disease, distant relapses were
the most common sites in patients from both the dabrafenib plus
trametinib (64% of patients with relapse) and placebo arms (54%).
These rates are consistent with reports from other adjuvant trials
with rates of distant relapse of 57% and 58% among patients who
experienced a relapse event in the CheckMate-238 (with nivolumab)
and KEYNOTE-054 (with pembrolizumab) trials, respectively.4,5
Lower rates of distant relapse (51%) have been reported in a ret-
rospective analysis of patients with stage III disease15; however, this
discrepancy may be explained, at least in part, by enhanced screening
in a trial setting.
OS in the EORTC 18071 trial at the primary RFS analysis was
immature at a median follow-up of 2.7 years16; however, extended
follow-up in the EORTC study2 has demonstrated signiﬁcant OS
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Fig 6. Forest plot of relapse-free survival by
subgroup. Number of patients are included in
parentheses. Only subgroups with $ 20 pa-
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beneﬁt. Updated OS analysis from the COMBI-AD trial is not reported
here because the number of events needed for the next prespeciﬁed
interim analysis of OS has not been reached. Statistical modeling using
aWeibull mixture cure-rate analysis that allows for the estimation of the
fraction of patients whomay never experience relapse provides a means
of assessing long-term outcomes in the absence of direct OS data.
Curves ﬁtted using the cure-rate model closely match Kaplan-Meier
curves of RFS, with estimated cure rates of 54% versus 37% in the
dabrafenib plus trametinib versus placebo arms, respectively. The
difference between those two estimated rates indicate the magnitude of
RFS effect that is preserved long term. In general, cure-rate modeling in
cancer trial settings has complemented standard survival analysis and
has been used in situations in which it is reasonable to assume that
a fraction of patients will never experience an event of interest—the
model allows for estimation of this fraction.13 Thesemodels have been
used successfully in multiple disease settings, including early-stage
cutaneous melanoma, gastric cancer, acute myeloid leukemia, and
multiplemyeloma.14,17-19 In a population-based study of patients with
cutaneous melanoma, cure-rate modeling demonstrated signiﬁcant
differences in cure rate on the basis of disease stage at diagnosis.17 In
patients with stage III melanoma, 10-year RFS rates of approximately
35% have been reported with a decreasing frequency of RFS events
over time, which indicates that a subset of patients experienced long-
termRFS.15,20 Additional validation of the utility of this approachwith
extended follow-up in patients receiving adjuvant therapy for mel-
anoma is warranted, including correlation with OS data.
The COMBI-AD trial was designed to evaluate 12 months of
adjuvant therapy with dabrafenib plus trametinib. No patients were
receiving treatment—last dose of study drug was administered to the
last patient in December 2015—during this extended follow-up period.
Because no additional drug-related toxicities were anticipated, safety
results were not updated at this data cutoff. At the primary analysis,6 the
most common adverse events reported in the combination therapy arm
were pyrexia (any grade, 63%; grade 3 and 4, 5%), fatigue (47%; 4%),
and nausea (40%; 1%). These adverse events are similar to those re-
ported in phase III trials of dabrafenib plus trametinib in patients with
stage IIIC unresectable melanoma or stage IV metastatic melanoma
with BRAFV600E or V600Kmutations.7,8 Health-related quality-of-life
data demonstrated that adjuvant treatment with dabrafenib plus tra-
metinib did not negatively affect patient-reported quality of life during
the treatment phase or in long-term follow-up.21
Patients with high-risk resectable melanoma represent a broad
and diverse group; therefore, there is great clinical interest in
understanding outcomes according to baseline characteristics.
Subgroup analysis of RFS in this study demonstrated that the RFS
beneﬁt observed with dabrafenib plus trametinib versus placebo
was similar regardless of baseline disease stage, metastatic load, or
tumor ulceration status. This is comparable to results from sub-
group analyses of data from the CheckMate-238 and KEYNOTE-
054 trials, which demonstrated improved RFS with nivolumab and
pembrolizumab, respectively, across subgroups.4,5 Although com-
parisons between clinical trials should be interpreted cautiously,
2-year RFS rates in patients with stage IIIB/C disease (per AJCC
7th edition) were similar in the nivolumab arm of the CheckMate-
238 trial (64%)4 and in the dabrafenib plus trametinib arm of the
COMBI-AD trial (63%). All patients in COMBI-AD had BRAF-
mutant disease compared with 41% of patients in the nivolumab
arm of CheckMate-238 (62% 2-year RFS rate among patients with
BRAF-mutant melanoma). To date, RFS on the basis of AJCC 8th
edition10 criteria for the CheckMate-238 and KEYNOTE-054 trials
has not been published, and it remains to be seen whether results
from these trials will be similar when patient disease-stage sub-
groups are categorized according to these new criteria. In the
COMBI-AD trial, we observed a consistent beneﬁt favoring dab-
rafenib plus trametinib across subgroups according to AJCC 8th
edition criteria.
Overall, the updated results with longer follow-up conﬁrm an
RFS beneﬁt in patients who are treated with dabrafenib plus
trametinib compared with placebo-treated patients. Subgroup
analysis supports the use of dabrafenib plus trametinib regardless
of clinical and pathologic factors at initiation of therapy on the
basis of similar RFS beneﬁt.
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Appendix
Table A1. Patient Baseline Demographics and Disease Characteristics
Characteristic Dabrafenib Plus Trametinib (n = 438) Placebo (n = 432)
Median age, years (range) 50 (18-89) 51 (20-85)
Sex, No. (%)
Male 244 (56) 239 (55)
Female 194 (44) 193 (45)
BRAF mutation status, No. (%)
V600E 397 (91) 395 (91)
V600K* 41 (9) 37 (9)
ECOG performance status, No. (%)
0 405 (92) 390 (90)
1 33 (8) 41 (9)
Unknown 0 1 (, 1)
Disease stage (AJCC 7th edition), No. (%)
IIIA 83 (19) 71 (16)
IIIB 169 (39) 187 (43)
IIIC 181 (41) 166 (38)
III (unspeciﬁed) 5 (1) 8 (2)
No. of positive lymph nodes†
1 177 (40) 183 (42)
2 or 3 158 (36) 150 (35)
$ 4 73 (17) 72 (17)
Type of lymph node involvement
Microscopic 152 (35) 157 (36)
Macroscopic 158 (36) 161 (37)
Not reported 128 (29) 114 (26)
Primary tumor ulceration
Yes 179 (41) 177 (41)
No 253 (58) 249 (58)
Unknown 6 (1) 6 (1)
In-transit disease
Yes 51 (12) 36 (8)
No 387 (88) 395 (91)
Unknown 0 1 (, 1)
Abbreviations: AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group.
*One patient had a BRAF V600E mutation and a BRAF V600K mutation and is included in the V600K subset.
†Reported for patients with available data.
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Table A2. Patient Disposition
Variable
Dabrafenib
(n = 435)
Trametinib
(n = 435)
Placebo to Match
Dabrafenib (n = 432)
Placebo to Match
Trametinib (n = 432)
Patients treated, No. (%)
Treatment ongoing as of data cutoff 0 0 0 0
End of treatment 435 (100) 435 (100) 432 (100) 432 (100)
Treatment status, No. (%)
Completed scheduled treatments 272 (63) 277 (64) 227 (53) 227 (53)
Prematurely discontinued treatment 163 (37) 158 (36) 205 (47) 205 (47)
Patient status, No. (%)
Died 75 (17) 75 (17) 103 (24) 103 (24)
In follow-up 313 (71) 313 (71) 264 (61) 264 (61)
Withdrawn from study 50 (11) 50 (11) 65 (15) 65 (15)
Reason for study withdrawal, No. (%)
Lost to follow-up 11 (3) 11 (3) 19 (4) 19 (4)
Investigator discretion 5 (1) 5 (1) 4 (, 1) 4 (, 1)
Withdrew consent 34 (8) 34 (8) 42 (10) 42 (10)
Table A4. Disease Stage on the Basis of AJCC 7th and 8th Editions
Disease Stage on the Basis of AJCC 7th Edition
Disease Stage on the Basis of AJCC 8th Edition
TotalStage IIIA Stage IIIB Stage IIIC Stage IIID Missing
Dabrafenib plus trametinib (n = 438), No. (%)
Stage IIIA 44 (10) 30 (7) 9 (2) 0 0 83 (19)
Stage IIIB 5 (1) 92 (21) 72 (16) 0 0 169 (39)
Stage IIIC 1 (, 1) 22 (5) 136 (31) 22 (5) 0 181 (41)
Missing 0 1 (, 1) 0 0 4 (, 1) 5 (1)
Total 50 (11) 145 (33) 217 (50) 22 (5) 4 (, 1) —
Placebo (n = 432), No. (%)
Stage IIIA 30 (7) 31 (7) 10 (2) 0 0 71 (16)
Stage IIIB 9 (2) 100 (23) 78 (18) 0 0 187 (43)
Stage IIIC 0 23 (5) 126 (29) 17 (4) 0 166 (38)
Missing 0 0 0 0 8 (2) 8 (2)
Total 39 (9) 154 (36) 214 (50) 17 (4) 8 (2) —
Abbreviation: AJCC, American Joint Committee on Cancer.
Table A3. Summary of RFS Events and Average Hazards by Time Interval
Time, Months
Dabrafenib + Trametinib (n = 438) Placebo (n = 432)
Patients at
Risk at the
Beginning of
Interval, No.
RFS Events
in the
Interval, No.
Censored
Patients in
the Interval,
No.
Average
Hazard in the
Time Interval
Patients at
Risk at the
Beginning of
Interval, No.
RFS Events
in the
Interval, No.
Censored
Patients in the
Interval, No.
Average Hazard
in the Time
Interval
0 to , 6 438 18 29 0.0074 432 137 15 0.0656
6 to , 12 391 30 7 0.0135 280 49 12 0.0325
12 to , 24 354 85 7 0.0231 219 44 7 0.019
24 to , 36 262 30 5 0.0102 168 17 4 0.009
36 to , 60 227 14 211 0.0038 147 7 139 0.021
Abbreviation: RFS, relapse-free survival.
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